Effects of steatotic liver disease and cardiometabolic risk factors in MASLD on adverse pregnancy outcomes

Abstract

Aim: A new definition of metabolic dysfunction-associated steatotic liver disease (MASLD) was proposed in 2023; however, its impact on adverse pregnancy outcomes (APOs) remains undetermined. This study aimed to comprehensively analyze the association between MASLD and the risk of APOs, and to evaluate the relative contributions of its components - steatotic liver disease (SLD) and cardiometabolic risk factors (CMRF).

Methods: This retrospective cohort study enrolled 4,118 pregnant women admitted to the hospital between March 2020 and December 2022. Participants were categorized into MASLD and non-MASLD groups based on MASLD status. The non-MASLD group was further divided into three subgroups according to the presence of SLD and CMRF. Adjusted relative risks (aRRs) for APOs were estimated using modified Poisson regression analysis, adjusting for relevant covariates.

Results: The prevalence of MASLD among pregnant women was 7.3%. MASLD was associated with elevated risks of cesarean section (aRR = 1.459, 95%CI: 1.253-1.700, P < 0.001), gestational diabetes mellitus(aRR = 2.081, 95%CI: 1.711-2.530, P < 0.001), pregnancy-associated hypertension (aRR = 2.192, 95%CI: 1.541-3.118, P < 0.001), preterm birth (aRR = 1.826, 95%CI: 1.181-2.823, P = 0.007), and large-for gestational-age neonates (aRR = 2.024, 95%CI: 1.488-2.754, P < 0.001). Compared with the CMRF-only group, the MASLD group showed higher risks of cesarean section (aRR = 1.387, 95%CI: 1.177-1.634, P < 0.001), gestational diabetes mellitus (aRR = 1.734, 95%CI: 1.405-2.139, P < 0.001), pregnancy-associated hypertension (aRR = 1.606, 95%CI: 1.105-2.333, P = 0.013), and large-for-gestational-age neonates (aRR = 1.845, 95%CI: 1.318-2.581, P < 0.001). No significant differences in risk were observed between the MASLD and SLD-only groups.

Conclusion: MASLD during pregnancy is associated with an increased risk of several APOs, with SLD appearing to play a more critical role than CMRF.

Keywords

Metabolic dysfunction-associated steatotic liver disease (MASLD) / pregnancy / steatotic liver disease (SLD) / cardiometabolic risk factors (CMRF) / adverse pregnancy outcomes (APOs)

References

[1] Huh Y,Nam GE.Recent epidemiology and risk factors of nonalcoholic fatty liver disease.J Obes Metab Syndr2022;31:17-27 PMCID:PMC8987457

[2] Wu T,Mo S.Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.J Gastroenterol Hepatol2024;39:1636-47

[3] Hershman M,Kushner T.Implications of nonalcoholic fatty liver disease on pregnancy and maternal and child outcomes.Gastroenterol Hepatol (N Y)2019;15:221-8 PMCID:PMC6696596

[4] Zhang ZC,Xiao LL.Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice.J Hepatol2015;63:1466-75

[5] Targher G,Lonardo A,Barbui C.Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis.J Hepatol2016;65:589-600

[6] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[7] Marchesini G,Bianchi G.Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.Diabetes2001;50:1844-50

[8] Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86. PMCID:PMC10653297

[9] Song R,Zhang Y,Chen Z.Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.Liver Int2024;44:1051-60

[10] Hagström H,Ludvigsson JF.Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease.Liver Int2016;36:268-74

[11] Hong S,Kwak SH.A comparison of predictive performances between old versus new criteria in a risk-based screening strategy for gestational diabetes mellitus.Diabetes Metab J2020;44:726-36 PMCID:PMC7643588

[12] Sarkar M,Dodge JL.Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes.J Hepatol2020;73:516-22 PMCID:PMC7438303

[13] Herath RP,Ekanayake CD,Kodithuwakku SUA.Non-alcoholic fatty liver disease and pregnancy complications among Sri Lankan women: a cross sectional analytical study.PLoS One2019;14:e0215326 PMCID:PMC6461248

[14] Qian Y,Fan X.Nonalcoholic fatty liver disease and adverse pregnancy outcomes in women with normal prepregnant weight.J Clin Endocrinol Metab2023;108:463-71

[15] Chai TY,George J,Cheung NW.Elevated hepatic steatosis index is associated with the development of adverse maternal, but not adverse neonatal, outcomes: a retrospective cohort study.Int J Womens Health2023;15:589-98 PMCID:PMC10108907

[16] Zhou BG,Jiang X,She Q.Non-alcoholic fatty liver disease and gestational diabetes mellitus: a bidirectional two-sample mendelian randomization study.BMC Endocr Disord2024;24:40 PMCID:PMC10953072

[17] Niu C,Khalid N.Cardiovascular complications during delivery hospitalizations in patients with nonalcoholic fatty liver disease in pregnancy.Eur J Gastroenterol Hepatol2024;36:1141-8

[18] Ipsen DH,Tveden-Nyborg P.Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.Cell Mol Life Sci2018;75:3313-27 PMCID:PMC6105174

[19] Lechner K,Kränkel N.High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation.Metab Syndr Relat Disord2020;18:176-85 PMCID:PMC7196362

[20] Birkenfeld AL.Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.Hepatology2014;59:713-23 PMCID:PMC3946772

[21] DeFronzo RA.Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.Diabetes Care1991;14:173-94

[22] Meex RCR.Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.Nat Rev Endocrinol2017;13:509-20

[23] Catalano PM.Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child.BMJ2017;356:j1 PMCID:PMC6888512

[24] criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline.Diabetes Res Clin Pract2014;103:341-63

[25] Woollett LA,Jones HN.Roles of maternal HDL during pregnancy.Biochim Biophys Acta Mol Cell Biol Lipids2022;1867:159106

[26] Liu PJ,Ma L.The predictive ability of two triglyceride-associated indices for gestational diabetes mellitus and large for gestational age infant among chinese pregnancies: a preliminary cohort study.Diabetes Metab Syndr Obes2020;13:2025-35 PMCID:PMC7305827

[27] Brereton MF,Shimomura K.Hyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic β-cells.Nat Commun2016;7:13496 PMCID:PMC5123088

[28] Schmieder RE.End organ damage in hypertension.Dtsch Arztebl Int2010;107:866-73 PMCID:PMC3011179

[29] National Health and Family Planning Commission of the People’s Republic of China. Criteria of weight for adults (WS/T 428-2013). Beijing: Standards Press of China; 2013. (In Chinese) Available from: https://www.nhc.gov.cn/wjw/yingyang/201308/a233d450fdbc47c5ad4f08b7e394d1e8.shtml. [Last accessed on 28 Jul 2025]

[30] National Health Commission of the People’s Republic of China. Standard of recommendation for weight gain during pregnancy period (WS/T 801-2022). Beijing: Standards Press of China; 2022. (In Chinese) Available from: https://www.nhc.gov.cn/wjw/c100311/202208/deb61e5c2299451ea1b957b0672272b3.shtml. [Last accessed on 28 Jul 2025]

[31] Graif M,Baraz M.Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease.Invest Radiol2000;35:319-24

[32] Brunt EM,Di Bisceglie AM,Bacon BR.Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.Am J Gastroenterol1999;94:2467-74

[33] Metzger BE, Gabbe SG, Persson B, et al; International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676-82. PMCID:PMC2827530

[34] American college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Hypertension in pregnancy: report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy.Obstet Gynecol2013;122:1122-31

[35] Goldenberg RL,Iams JD.Epidemiology and causes of preterm birth.Lancet2008;371:75-84 PMCID:PMC7134569

[36] National Health Commission of the People’s Republic of China. Growth standard for newborns by gestational age (WS/T 800-2022). Beijing: Standards Press of China; 2022. (In Chinese) Available from: https://www.nhc.gov.cn/wjw/c100311/202208/07787ef64ba34fe1bc8bbdae9fd0d4e5.shtml. [Last accessed on 28 Jul 2025].

[37] Borovac-Pinheiro A,Cecatti JG.Postpartum hemorrhage: new insights for definition and diagnosis.Am J Obstet Gynecol2018;219:162-8

[38] Committee on Practice Bulletins-Obstetrics. Practice bulletin No. 183: postpartum hemorrhage.Obstet Gynecol2017;130:e168-86

[39] Sattar N.Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?.BMJ2002;325:157-60 PMCID:PMC1123678

[40] Shulman GI.Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease.N Engl J Med2014;371:1131-41

[41] Choudhury AA.Gestational diabetes mellitus - a metabolic and reproductive disorder.Biomed Pharmacother2021;143:112183

[42] Nasioudis D,Kanninen TT.Dyslipidemia in pregnancy and maternal-fetal outcome.Minerva Ginecol2019;71:155-62

[43] Monteiro R.Chronic inflammation in obesity and the metabolic syndrome.Mediators Inflamm2010;2010:1-10 PMCID:PMC2913796

[44] Richard AJ,Elks CM. Adipose tissue: physiology to metabolic dysfunction. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555602/. [Last accessed on 21 Jul 2025].

[45] Coates D,Wilson A.Indications for, and timing of, planned caesarean section: a systematic analysis of clinical guidelines.Women Birth2020;33:22-34

[46] Lee SM,Choi ES.Metabolic dysfunction-associated fatty liver disease and subsequent development of adverse pregnancy outcomes.Clin Gastroenterol Hepatol2022;20:2542-50.e8

[47] Nassir F.NAFLD: mechanisms, treatments, and biomarkers.Biomolecules2022;12:824 PMCID:PMC9221336

[48] Svenvik M,Brudin L.Early prediction of spontaneous preterm birth before 34 gestational weeks based on a combination of inflammation-associated plasma proteins.Front Immunol2024;15:1415016 PMCID:PMC11284114

[49] Ismaiel A.Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review.Front Med2019;6:202 PMCID:PMC6763690

[50] Scifres CM,Orris S.Metabolic factors and perinatal outcomes among pregnant individuals with mild glucose intolerance.Diabetes Res Clin Pract2024;216:111830

[51] Byrne CD.Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.Proc Nutr Soc2013;72:412-9

[52] Lastra G,Johnson MS.Salt, aldosterone, and insulin resistance: impact on the cardiovascular system.Nat Rev Cardiol2010;7:577-84

[53] Metzger BE, Lowe LP, Dyer AR, et al; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991-2002.

[54] Vogel JP,Moller AB,Bonet M.The global epidemiology of preterm birth.Best Pract Res Clin Obstet Gynaecol2018;52:3-12